跳至主要内容
临床试验/NCT00534183
NCT00534183已完成不适用

Metabolic Profile and Anthropometric Changes in Schizophrenia

Central Institute of Psychiatry, Ranchi, India1 个研究点 分布在 1 个国家目标入组 2,006 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,006
试验地点
1
主要终点
Study of metabolic profile

研究概览

简要总结

"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

详细描述

we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18-40 years
  • Diagnosis of schizophrenia
  • Drug naive on admission

排除标准

  • Other psychiatric co-morbidity
  • History of severe physical illness
  • Alcohol and substance abuse or dependence
  • History of pre-existing diabetes or hypertension
  • Family history of hypertension or diabetes

研究组 & 干预措施

1

Experimental

Olanzapine

干预措施: Olanzapine (Drug)

2

Active Comparator

Risperidone

干预措施: Risperidone (Drug)

3

Active Comparator

haloperidol

干预措施: Haloperidol (Drug)

结局指标

主要结局

Study of metabolic profile

时间窗: 6 weeks

次要结局

  • Study of obesity and diabetes(6 weeks)

研究者

发起方
Central Institute of Psychiatry, Ranchi, India
申办方类型
Other

研究点 (1)

Loading locations...

相似试验